ArticleScientific reports2025
Novel cancer subtyping method guided by tumor-normal sample in latent space of transcriptomic variational autoencoder.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumorigenesis is a microevolutionary process in which heterogeneous tumor cells adapt within a complex microenvironment. Current tumor omics analyses often focus exclusively on tumor samples, overlooking the valuable insights that normal tissues can provide. To address this gap, we introduce VaDTN (Variational Autoencoder-Derived Tumor-to-Normal), a pan-cancer framework that integrates transcriptomic data from both tumor and normal samples into a unified latent space. By measuring each tumor's "distance" from a normal reference within this latent space, VaDTN reveals subtle molecular shifts linked to tumor evolution and heterogeneity. We applied VaDTN to six representative cancers (SKCM, BRCA, LIHC, LUSC, STAD, and PAAD), identifying distinct subtypes characterized by unique transcriptional profiles. Notably, four cancer types (SKCM, BRCA, LIHC, and STAD) displayed significant survival stratification based on these subtype groupings, underscoring the clinical relevance of the distance-based approach. This reference-centered perspective thus provides a refined lens for dissecting intra-tumor diversity and guiding potential precision oncology strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.